The Advancement of Stem Cell Technology
At the Miami Stem Cell Treatment Center we provide consultation relating to clinical research and deployment of stem cell therapy for patients suffering from diseases that may have limited treatment options. Stem cell therapy is not for everyone – but under the right circumstances and under the right conditions – there may be an opportunity for stem cell therapy to be effective. But stem cell therapy is not, at present time, is not the holy grail we all would like it to be.
Our expertise involves a deep commitment and long-term understanding, knowledge and experience in clinical research and the advancement of regenerative medicine.
We firmly support respected guidance regarding stem cell therapy indicating that it should be autologous, include ONLY minimal manipulation of regenerative cells, and be consistent with homologous use.
We do NOT advise the addition of chemicals or enzymes to produce the stromal vascular fraction (SVF).
We believe that treatment protocols ought to be reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection (OHRP) – or – United States F.D.A,
Because we are committed to the principles and ideals of regenerative medicine, we are continuously updating, researching, and learning more on how to help patients and advance the state of the art of regenerative medicine. Accordingly we provide all patients who are interested in considering stem cell therapy an honest opinion as to the potential benefits and risks of stem cell therapy for their presenting condition.
At the Miami Stem Cell Treatment Center we will review your medical records and condition, and then consider an array of ongoing IRB-approved protocols, registered with Clnicaltrials.gov, a service of the National Institute of Health and the National Library of Congress, to provide patients with a wide variety of treatment options and considerations – for medical disorders that may benefit from adult stem cell-based regenerative therapy.